Who Qualifies for Hair Loss Treatment and Who Should Not
Who is a good candidate for each hair loss treatment, and who should avoid them?
Most people start by picking a product, and that's the wrong end of the problem. What decides your result is the cause of the loss, how much living follicle is still sitting in the thin area, and whether you can safely take the drug at all. Get those three right and the product choice mostly sorts itself out.
Every hair loss treatment with strong evidence works by rescuing living, miniaturized follicles, so candidacy is decided by how much viable follicle remains rather than by which product you pick.
How does the pattern and stage of hair loss determine which treatment will actually work?
The useful question isn't how much hair you've lost. It's how much fine, wispy hair is still hanging on inside the thin patch, because that's the tissue any drug has to work with. A scalp showing fuzz under magnification is a treatable scalp; a smooth one with no visible pores has already closed the file.
Medication can only restore follicles that are still alive and miniaturized, which is why the crown and mid-scalp show the strongest regrowth in trials while a smooth, pore-free scalp at Norwood 6 or 7 shows none.
Which people should not take oral finasteride or dutasteride?
There's exactly one absolute exclusion here, and everything else is a conversation you want before the first tablet rather than after it. The trial numbers are small but they're real, and a minority of users report symptoms that persist after they stop. Dutasteride raises the stakes on that, since its half-life runs in weeks rather than hours, so a bad reaction takes far longer to clear.
- Pregnancy or possible pregnancy: Absolute exclusion, and don't handle broken or crushed tablets either.
- Sexual side effects: One to two percent each in the pivotal trials against roughly one percent on placebo.
- PSA monitoring past forty-five: Finasteride cuts the reading about a third at twelve months, so get a baseline.
- Active depression or mood history: Decide with a prescriber, not through an online questionnaire.
Finasteride and dutasteride are absolutely contraindicated in any woman who is pregnant, breastfeeding, or could become pregnant, because blocking 5-alpha-reductase interferes with formation of the male external genitalia in a developing fetus.
Who is a poor candidate for topical minoxidil, and what makes people stop using it?
Minoxidil barely has a medical exclusion list, yet the abandonment rate is enormous, and that gap tells you the real barrier is practical rather than clinical. Most people who quit do it in the first few weeks, mid-shed, at exactly the wrong moment.
- The shedding phase: Early weeks look worse as the drug resets follicles into a new growth cycle.
- Propylene glycol irritation: Liquid solutions itch and flake on eczema-prone scalps; the foam drops that ingredient.
- Cardiovascular history: Dizziness, palpitations and ankle swelling get reported, so clear it with a prescriber.
- A cat in the house: Cats are acutely sensitive, and a tiny exposure can cause severe illness or death.
Minoxidil demands twice daily application to a dry scalp indefinitely and its entire benefit disappears within months of stopping, which is why abandonment rather than any medical exclusion defeats most users.
What makes someone a good or bad candidate for a hair transplant?
A transplant redistributes hair, it never adds any, so this is arithmetic before it's cosmetics. Your donor zone at the back and sides is a fixed lifetime budget spread across every session you'll ever have. The fastest way to burn it is operating while the pattern is still moving.
| Criteria | Strong Candidate | Poor Candidate |
|---|---|---|
| Pattern stability | Settled, usually past twenty-five | Still progressing, under twenty-five |
| Donor density | Average or better in the permanent occipital zone | Below average, or thinning diffusely |
| Hair characteristics | Thick caliber, wavy, low colour contrast | Fine, straight, dark hair on pale skin |
| Diagnosis | Androgenetic pattern loss | Scarring alopecia or active alopecia areata |
| The request | One priority zone, modest hairline | The hairline he had at eighteen |
Because a transplant only moves existing hair, surgeons commonly decline men under about twenty-five, ask for a period of medical stabilization first, and require ongoing finasteride or minoxidil afterwards to protect the untransplanted hair.
How do age and the pace of ongoing loss change when treatment should start?
Timing beats product selection, and it isn't close. Since these drugs hold living follicles rather than raise dead ones, the hair you'll have at fifty is mostly decided by when you started, not by which of the two proven treatments you chose. A man who holds from Norwood 2 finishes ahead of a man who responds beautifully from Norwood 5, because the second man's ceiling is lower.
Because these drugs preserve living follicles rather than restore dead ones, how early you start sets a permanently higher ceiling than any difference between the two proven treatments.
Which medical conditions and other medications rule someone out of treatment?
Very little forbids hair loss treatment outright. Plenty of it makes treatment pointless until something else gets fixed, and that's the distinction to hold onto. Adding minoxidil on top of an unaddressed driver treats the symptom while the cause keeps running.
Scarring alopecias are exclusions rather than delays, because the follicle is replaced by fibrous tissue and the narrow window in which anti-inflammatory treatment can halt the damage closes permanently.
How does candidacy differ for women compared with men?
The starting assumption is what differs. A thinning man is presumed androgenetic until something suggests otherwise, while a thinning woman needs the cause established first, since thyroid disease, iron deficiency, polycystic ovary syndrome, postpartum shedding and traction all sit in the same picture. That's why a woman's first appointment often produces blood tests instead of a prescription.
| Criteria | Women | Men |
|---|---|---|
| First step | Workup and bloods before any plan | Presumed pattern loss, treat directly |
| Anchor treatment | Five percent minoxidil foam once daily | Oral finasteride, often alongside minoxidil |
| 5-alpha-reductase inhibitors | Contraindicated if pregnancy is possible; off label and specialist-only after menopause | Standard first line |
| Extra route | Spironolactone or cyproterone acetate with potassium monitoring | Not applicable |
| Transplant fit | Often declined, since the donor zone thins too | Usually viable once the pattern is stable |
Female pattern loss is frequently diffuse enough to include the occipital donor zone, so the women who do well from transplantation are those with localized loss such as traction alopecia, where the donor supply is intact.
Which causes of shedding need a diagnosis before any baldness treatment begins?
Pattern loss thins specific zones and leaves the back and sides untouched. Almost everything else thins the whole head or attacks one patch, and that single distinction does most of the diagnostic work before anyone fills out a lab form.
- Telogen effluvium: Diffuse shed two to three months after a trigger, self-limiting under six months.
- Scarring alopecias: Burning, tenderness, scaling and lost follicular openings, and the damage is permanent.
- Alopecia areata: Smooth round patches with short exclamation-mark hairs at the border, autoimmune rather than androgenic.
- Nutritional causes: Iron, protein, zinc and vitamin A toxicity are documented; biotin deficiency is genuinely rare.
Loss of visible follicular openings marks a scarring alopecia, so every month spent applying minoxidil to that scalp is permanent loss that anti-inflammatory treatment might have prevented.
What expectations separate a satisfied patient from a disappointed one?
Nearly every disappointed patient came in for regrowth and received preservation. In the five year finasteride data, roughly ninety percent of treated men kept or improved their hair while about three quarters of untreated men lost more, and about half showed visible regrowth on blinded photographic review. The honest promise is that your hair in five years looks like it does today rather than like it would have.
- Months one to three: Nothing visible, and the shedding phase can make it look worse. Judging here guarantees a false verdict.
- Month six: The first genuine assessment point, read from standardized photographs rather than bathroom mirror impressions.
- Month twelve: The fair verdict. If regrowth is coming, this is where it has shown up.
- Every three months after: Fixed distance, fixed lighting, same angles. Daily checks measure noise, not trend.
- The day you stop: The rescued follicles resume miniaturizing and the accumulated benefit unwinds.
The benefit of both drugs depends entirely on continued use, with finasteride's effect reversing fully within about twelve months of stopping, so treatment is a subscription rather than a course.
Who is suited to in-office options like laser devices and platelet rich plasma?
Treat these as amplifiers, never replacements. The right candidate is already on minoxidil or a 5-alpha-reductase inhibitor, has stabilized, and wants an incremental gain, or can't tolerate the drugs and has accepted a weaker option with open eyes.
- Low level laser therapy: 620 to 680 nanometres, modest real gains, but most trials ran twenty-six weeks or less.
- Platelet rich plasma: Three to four induction sessions a month apart, then maintenance; annual cost exceeds both drugs combined.
- Platelet rich plasma exclusions: Platelet disorders, anticoagulant therapy, immunosuppression, keloid tendency, active malignancy, local infection.
- Microneedling: Cheap adjunct that lifts hair count alongside topical minoxidil; skip it on irritated skin.
Laser therapy, platelet rich plasma and microneedling all decay without repetition, so they suit someone already stabilized on medication and do least for a scalp that is already smooth.
